Preliminary Program. Subject to Changes & Updates.
Time | Session |
---|---|
08:00 | Welcome Coffee |
08:45 | Opening Remarks – Organizers |
08:50 | Keynote I: Mathias Vormehr – Senior Director Cancer Vaccines – BioNTech – “mRNA vaccines for the treatment of cancer” |
09:30 | Company Presentations I: Constance Ciaudo Beyer – DeepLife – “Digital twin of cells for drug discovery” Alice Ghidini – SENISCA – “Oligonucleotide senotherapeutics for the diseases of ageing“ Dominik Witzigmann – NanoVation Therapeutics – “Next-generation LNP technologies to enable RNA delivery beyond the liver” |
10:30 | Ingrid B. Müller – Swiss Federal Institute of Intellectual Property – “The Patent Landscape of RNA Therapeutics” |
10:40 | Coffee Break |
11:10 | Clinical RNA Therapeutics in Rare Diseases : Matias Wagner – Institute of Human Genetics, Klinikum rechts der Isar, Technical University Munich – “A Novel Antisense Oligonucleotide for the Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy: A First-in-Patient Report in a Preterm Infant with Refractory Status Epilepticus” |
11:35 | Panel – RNA Therapeutics – Future Developments: Marc Abramowicz – Professor & Head, Genetic Medicine, University Hospital Geneva Jasmin Barman-Aksözen – Triemli Hospital & University of Zurich Matias Wagner – Institute of Human Genetics, Klinikum rechts der Isar, Technical University Munich Annemieke Aartsma-Rus – Professor of Human Genetics – University of Leiden Mathias Vormehr – Senior Director Cancer Vaccines – BioNTech Moderated by Jonathan Hall |
12:00 | Lunch & Poster Session & Networking & Sponsor Presentations 13:15 Lunchtalk: Clement Quan – Alithea Genomics – “RNA sequencing at scale: Next generation drug and biomarker discovery” |
14:00 | Keynote II: Annemieke Aartsma-Rus – Professor of Human Genetics – University of Leiden – “From Duchenne exon skipping to N=1 treatment: Applying lessons learned for (very) rare disease patients” |
14:40 | Young Scientists Career Talks: Alice Ghidini – VP Oligotherapeutics Development – SENISCA – “Bridging Chemistry and Preclinical Development of RNA Therapeutics, with a biophysical perspective” Larissa Grolimund – Global Regulatory Affairs CMC Manager – CSL Behring – “From RNA Lab to Regulatory Desk” Mateusz Mendel – Senior Scientist Lead Discovery – Roche – “From RNA Biology to Drug Discovery: Navigating an Early Career in Industry” |
15:00 | Translational Academic Projects Felix Baier – CALDRE & University of Bern – “Liver specific therapies to combat cholestatic diseases” Algera Goga – University Children’s Hospital Zurich & University of Zurich – “Antisense oligonucleotides as splicing modulators for an N=1 trial of Arginase deficiency” Rory Johnson – UC Dublin & University of Bern – “Linn Therapeutics: CRISPR-powered non-coding RNA therapeutics for oncology” Raja Prince – BLEEDnFIRE Therapeutics & University of Bern “Advancing Hemophilia Care: siRNA Targeting Protein S for Optimal Hemostasis and Bone Health” |
15:55 | Coffee Break |
16:25 | Company Presentations II Troels Koch – MiNA Therapeutics – “MiNA therapeutics: Upregulating gene xpression” Covadonga Pañeda – Altamira Therapeutics- “OligoPhore and SemaPhore for extrahepatic delivery of therapeutic RNA” Keith Phillips – Grünenthal – “New Horizons in RNA Therapeutics: Unlocking Peripheral Neuronal Delivery to Target Chronic Pain and Sensory Disorders” Felix Schumacher – Roche – “New developments in the delivery of therapeutic oligos to eye and brain” |
17:35 | Keynote III: Eric Miska – Co-founder Storm Therapeutics & University of Cambridge, United Kingdom – “New ways of targeting and delivering RNA” |
18:15 | Concluding Remarks – Organizers |
18:20 | Apéro |